Últimas noticias sobre Citizens (NYSE:CIA) Bolsa

Citizens

Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

ANTX

RPHM

Compras de insiders en penny stocks como Reneo, AN2 Therapeutics y Citizens. ¿Qué revela sobre la confianza en estas empresas?

Insider Trading: Compras de penny stocks en Reneo Pharmaceuticals, AN2 Therapeutics y Citizens

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

CHINA SCORE INC by China Score, Inc.

Citizens (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) is preparing to release its quarterly earnings on Thursday, 2025-03-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Citizens to report an earnings per share (EPS) of $0.09.
Citizens bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 5.38% drop in the share price on the subsequent day.
Here's a look at Citizens's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.08</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.05</td>
<td>0.08</td>
<td>0.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748444499_0.png" alt="eps graph" />
<h3>Tracking Citizens's Stock Performance</h3>
Shares of Citizens were trading at $3.67 as of May 27. Over the last 52-week period, shares are up 26.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CIA/earnings">To track all earnings releases for Citizens visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

A Preview Of Citizens's Earnings

WIIM

Brighthouse Financial, Inc. - Common Stock

BWIN

CINF

ERIE

GSHD

HUIZ

ITIC

KMPR

KNSL

LMND

OSCR

PLMR

ROOT

RYAN

SKWD

TRUP

TWFG

ZBAO

Shares of insurance companies are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

<a href="https://api.newsfilecorp.com/redirect/7WJDjcAWVw">Citizens, Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>), a leading diversified financial services company specializing in life, living benefits, and final expense insurance, today announced Bryon Matthew Lewis, who serves as Citizens' global Vice President of Operations, is promoted to Chief Operating Officer, a newly created global position effective immediately, reporting to Jon Stenberg, President and Chief Executive Officer. This role will oversee Underwriting, New Business, Claims, and Corporate and Policyholder Services, which are critical activities as we continue delivering our promises to policyholders.

Management

Citizens' VP Of Operations Bryon Matthew Lewis Appointed Chief Operating Officer, Effective Immediately

AAPL

ABCB

ALGM

APPF

Adtalem Global Education Inc. Common Stock

ATGE

BAFN

BBVA

BHLB

BOOT

CACC

CHKP

CIVB

CMCSA

CNOB

COUR

CSWI

CVCO

DECK

FBIZ

FCFS

FFWM

FINW

FISI

FLWS

FRME

GSIT

INTC

KLAC

KRNY

LPLA

MBLY

MBUU

NTCT

ONEW

PFSI

REAL

SCSC

SHEL

SILC

SIRI

SKYW

STBA

STEL

Earnings Scheduled For January 30, 2025

<a href="https://api.newsfilecorp.com/redirect/NBYWPf4GkW">Citizens, Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>), a leading diversified financial services company specializing in life, living benefits, and final expense insurance, today announced it has filed a shelf registration statement (the "Shelf Registration") on Form S-3 with the United States Securities and Exchange Commission (the "SEC"), replacing a previous shelf registration statement on Form S-3 that will expire on November 30, 2024.
The replacement Shelf Registration will allow the Company to continue offering shares under its Stock Investment Plan (SIP), which has been in place since 2001. Under the SIP, the Company can either issue new shares to investors or facilitate purchase of shares on the open market. This Shelf Registration reduced the number of shares the Company could offer under the SIP to 5 million shares from 15 million shares registered under the previous S-3, demonstrating the Company's commitment to shareholder returns.

Offerings

Citizens Announces It Has Filed A Shelf Registration Statement On Form S-3 With The U.S. SEC, Replacing A Previous Shelf Registration Statement On Form S-3 That Will Expire On November 30, 2024

Citizens Inc. Files Prospectus For Up To 5M Shares Of Co's Class A Common Stock Under Stock Investment Plan

Citizens (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.08 by 37.5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $61.73 million which missed the analyst consensus estimate of $62.54 million by 1.29 percent. This is a 3.94 percent increase over sales of $59.39 million the same period last year.

Earnings Misses

Citizens Q3 EPS $0.05 Misses $0.08 Estimate, Sales $61.73M Miss $62.54M Estimate

Citizens (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) will release its quarterly earnings report on Tuesday, 2024-08-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Citizens to report an earnings per share (EPS) of $0.06.
Anticipation surrounds Citizens's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Here's a look at Citizens's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.09</td>
<td>0.21</td>
<td>0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>12.0%</td>
<td>-6.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<a href="https://www.benzinga.com/quote/CIA/earnings">To track all earnings releases for Citizens visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Citizens's Future Earnings

JNVR

KSPI

LGHL

STEC

VALU

Shares of companies within the broader financial sector are trading lower possibly amid overall market weakness.

The Dow Jones index closed higher by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Reneo Pharmaceuticals</h3>
<ul>
<li>The Trade: Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) 10% owner Braden Michael Leonard b<a href="https://www.benzinga.com/sec/insider-trades/">ought a total of 271,826 share</a>s at an average price of $1.40. To acquire these shares, it cost around $380,598.</li>
<li>What's Happening: On Aug. 13, Reneo Pharmaceuticals posted a second-quarter loss of 16 cents per share.</li>
<li>What Reneo Pharmaceuticals Does: Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company.</li>
</ul>
<h3 class="wp-block-heading">AN2 Therapeutics</h3>
<ul>
<li>The Trade: AN2 Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,500,000 shares at</a> an average price of $1.04. To acquire these shares, it cost around $1.56 million.</li>
<li>What's Happening: On Aug. 13, AN2 Therapeutics posted a narrower-than-expected quarterly loss.</li>
<li>What AN2 Therapeutics Does: AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs.</li>
</ul>
<h3 class="wp-block-heading">Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) President and CEO Jon Stenberg <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,126 shares</a> at an average price of $2.73. The insider spent around $13,994 to buy those shares.</li>
<li>What's Happening: On Aug. 6, Citizens reported better-than-expected second-quarter financial results.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">Jim Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>

Citizens And 2 Other Penny Stocks Insiders Are Buying

Citizens shares are trading higher after the company reported better-than-expected Q2 financial results.

Citizens (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 33.33 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $62.08 million which beat the analyst consensus estimate of $59.24 million by 4.80 percent. This is a 6.08 percent increase over sales of $58.53 million the same period last year.

Earnings Beats

Citizens Q2 EPS $0.08 Beats $0.06 Estimate, Sales $62.08M Beat $59.24M Estimate

The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ARCA biopharma</h3>
<ul>
<li>The Trade: ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 408,777 shares at</a> an average price of $3.49. To acquire these shares, it cost around $1.4 million.</li>
<li>What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.</li>
<li>What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.</li>
</ul>
<h3 class="wp-block-heading">Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) President and CEO Jon Stenberg <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 4,580 shares at</a> an average price of $2.59. To acquire these shares, it cost around $11,862.</li>
<li>What's Happening: On July 1, Citizens President Jon Stenberg was appointed Chief Executive Officer.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
<h3 class="wp-block-heading">Willamette Valley Vineyards</h3>
<ul>
<li>The Trade: Willamette Valley Vineyards, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>) CEO James W Bernau <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,978 shares</a> at an average price of $3.92. The insider spent around $11,682 to buy those shares. </li>
<li>What's Happening: On May 13, the company said sales revenue for the three months ended March 31, 2024 and 2023 was $8,803,080 and $8,308,940, respectively.</li>
<li>What Willamette Valley Vineyards Does: Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis a<a href="https://www.benzinga.com/quote/aei/analyst-ratings">cquired a total of 10,000 shares</a> at an average price of $0.42. The insider spent around $4,200 to buy those shares.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">Douglas Elliman</h3>
<ul>
<li>The Trade: Douglas Elliman Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) Director Mark Zeitchick <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 40,000 shares</a> at an average price of $1.18. The insider spent $47,196 to buy those shares.</li>
<li>What's Happening: On July 2, Douglas Elliman announced that it secured a $50 million growth investment from Kennedy Lewis Investment Management.</li>
<li>What Douglas Elliman Does: Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39748049/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q2 Earnings</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

ABIO

CYAN

DOUG

WVVI

Citizens And 4 Other Stocks Under $5 Insiders Are Buying

Jon Stenberg is an experienced growth leader to further leverage Citizens' opportunities
Gerald W. Shields continues as Vice Chairman of the Board
Austin, Texas--(Newsfile Corp. - July 1, 2024) - <a href="https://api.newsfilecorp.com/redirect/QOMOGIWA51">Citizens, Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>), a leading diversified financial services company specializing in life, living benefits, and final expense insurance, today announces the planned transition of the Chief Executive Officer role. Jon Stenberg, who currently serves as Citizens' President, is appointed to the additional role of Chief Executive Officer effective July 1, 2024. Gerald W. Shields, who has served as CEO and Vice Chairman since 2020, will continue as Vice Chairman of the Company's Board of Directors.

Citizens, Inc. President Jon Stenberg Appointed CEO, Effective July 1, 2024; Gerald W. Shields, Who Has Served As CEO And Vice Chairman Since 2020, Will Continue As Vice Chairman

The Dow Jones index closed lower by around 10 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Citizens </h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cia#NYSE">CIA</a>) Director Terry Sam Maness <a href="https://www.benzinga.com/quote/CIA/analyst-ratings"> acquired a total of 1,000 shares </a> an average price of $2.14. To acquire these shares, it cost around $2,137.</li>
<li>What&rsquo;s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
<h3>Tecogen</h3>
<ul>
<li>The Trade: Tecogen Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/tgen#OTC">TGEN</a>) Director John Hatsopoulos <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 1,000 shares at </a> at an average price of $0.70. To acquire these shares, it cost around $700.</li>
<li>What&rsquo;s Happening: On March 13, Tecogen reported revenues of $5.9 million and a net loss of $1.8 million for the quarter ended Dec. 31, 2023.</li>
<li>What Tecogen Does: Tecogen Inc, designs, manufactures, markets, and maintains high-efficiency, ultra-clean cogeneration products. It operates in three business segments, namely Products, Services, and Energy Production.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38154597/neogen-maxeon-solar-technologies-and-3-stocks-to-watch-heading-into-tuesday"> Neogen, Maxeon Solar Technologies And 3 Stocks To Watch Heading Into Tuesday </a>
<h3>Silo Pharma </h3>
<ul>
<li>The Trade: Silo Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silo#NASDAQ">SILO</a>) CEO and President Eric Weisblum <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 1,000 shares </a> at an average price of $1.99. The insider spent around $1,988 to buy those shares.</li>
<li>What&rsquo;s Happening: Silo Pharma approved extension of previously announced stock repurchase program authorizing purchase of up to $1 million common stock until April 30.</li>
<li>What Silo Pharma Does: SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

SILO

TGEN

Citizens And 2 Other Stocks Under $3 Insiders Are Buying

The Dow Jones index closed higher by over 475 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Retractable Technologies </h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvp#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/quote/RVP/analyst-ratings"> acquired a total of 5,096 shares </a> an average price of $1.18. To acquire these shares, it cost around $6,024.</li>
<li>What&rsquo;s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
<h3>Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cia#NYSE">CIA</a>) Director James Keith Morgan <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,899 shares at </a> at an average price of $2.11. To acquire these shares, it cost around $12,469.</li>
<li>What&rsquo;s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/03/37975793/walgreens-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-cal"> Walgreens Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>
<h3>Journey Medical </h3>
<ul>
<li>The Trade: Journey Medical Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/derm#NASDAQ">DERM</a>) Director Lindsay A MD Rosenwald <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 10,000 shares </a> at an average price of $3.04. The insider spent around $30,400 to buy those shares.</li>
<li>What&rsquo;s Happening: On March 21, Journey Medical posted a profit for the fourth quarter.</li>
<li>What Journey Medical Does: Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

DERM

Journey Medical And 2 Other Stocks Under $4 Insiders Are Buying

The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Citizens </h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cia#NYSE">CIA</a>) President and CEO Gerald Shields <a href="https://www.benzinga.com/quote/CIA/analyst-ratings"> acquired a total of 17,466 shares </a> an average price of $2.26. To acquire these shares, it cost around $39,475.</li>
<li>What&rsquo;s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
<h3>AIM ImmunoTech</h3>
<ul>
<li>The Trade: AIM ImmunoTech Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aim#NYSE">AIM</a>) Director Nancy Bryan <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 38,462 shares at </a> at an average price of $0.39. To acquire these shares, it cost around $15,000.</li>
<li>What&rsquo;s Happening: On Feb. 8, AIM ImmunoTech reported topline results from Phase 2 study evaluating ampligen for the treatment of post-COVID conditions.</li>
<li>What AIM ImmunoTech Does: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/03/37889754/top-5-consumer-stocks-that-may-crash-this-month"> Top 5 Consumer Stocks That May Crash This Month </a>
<h3>Power Solutions International </h3>
<ul>
<li>The Trade: Power Solutions International, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/psix#OTC">PSIX</a>) 10% owner Neil Gagnon <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,392 shares </a> at an average price of $2.00. The insider spent around $10,784 to buy those shares.</li>
<li>What&rsquo;s Happening: On March 14, Power Solutions International announced fourth quarter and full year 2023 financial results.</li>
<li>What Power Solutions International Does: Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that primarily run on nondiesel fuels, including natural gas, propane, and gasoline.</li>
</ul>
<h3>Brightcove </h3>
<ul>
<li>The Trade: Brightcove Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcov#NASDAQ">BCOV</a>) 10% owner Brolin Jonathan <a href="https://www.benzinga.com/quote/BCOV/analyst-ratings"> acquired a total of 30,000 shares </a> at an average price of $1.88. The insider spent around $56,250 to buy those shares.</li>
<li>What&rsquo;s Happening: On Feb. 22, Brightcove reported fourth-quarter financial results and issued FY24 guidance below estimates.</li>
<li>What Brightcove Does: Brightcove Inc is a provider of cloud-based streaming technology and services.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

BCOV

PSIX

AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying

<a href="https://pro.benzinga.com/?utm_source=insights">According to Benzinga Pro</a> following are the gainers and losers in <a href="https://www.benzinga.com/money/insurance/">Insurance</a> industry for today's Intraday session. 
<h3>Gainers</h3>
<ul>
<li>Reliance Global Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) stock moved upwards by 18.84% to $0.61 during Monday's regular session. The current volume of 2.2 million shares is 0% of Reliance Global Group's average full-day volume over the last 100 days (last updated at 12:40 EST). The market value of their outstanding shares is at $2.7 million. </li>
<li>Crawford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) shares increased by 5.84% to $12.72. As of 12:40 EST, this security is trading at a volume of 45.1K shares, making up 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at 621963076. </li>
<li>Crawford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) stock rose 5.74% to $11.96. Trading volume for this security as of 12:40 EST is 2.8K, which is 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at 584686845. The company's, Q4 earnings came out today. </li>
<li>Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) stock rose 5.6% to $28.81. Trading volume for this security as of 12:40 EST is 193.7K, which is 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Intl General Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) stock increased by 5.13% to $12.48. Intl General Insurance's stock is trading at a volume of 69.6K shares as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $594.8 million. </li>
<li>Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) stock rose 4.48% to $4.46. As of 12:40 EST, Cheche Group's stock is trading at a volume of 14.1K, which is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $328.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) shares declined by 7.43% to $1.19 during Monday's regular session. Trading volume for Waterdrop's stock is 366.8K as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $484.7 million. </li>
<li>Ambac Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBC#NYSE">AMBC</a>) shares decreased by 6.98% to $15.06. As of 12:40 EST, Ambac Financial Group's stock is trading at a volume of 184.7K, which is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $731.7 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Maiden Holdings, Ltd. 6.625% Notes due 2046 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHLA#NYSE">MHLA</a>) stock declined by 6.95% to $15.13. As of 12:40 EST, this security is trading at a volume of 2.0K shares, making up 0% of its average full-day volume over the last 100 days. </li>
<li>American Coastal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) shares decreased by 5.8% to $11.21. American Coastal's stock is trading at a volume of 385.0K shares as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $556.6 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>SelectQuote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) shares decreased by 5.23% to $1.91. Trading volume for SelectQuote's stock is 378.7K as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $341.3 million. </li>
<li>Citizens (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) stock fell 4.77% to $2.6. Citizens's stock is trading at a volume of 18.9K shares as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $136.2 million. </li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACIC

AMBC

IGIC

Maiden Holdings, Ltd. 6.625% Notes due 2046

MHLA

RELI

SLQT

Insurance Stocks Moving In Monday's Intraday Session

The Dow Jones index closed lower by more than 60 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Retractable Technologies </h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvp#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/quote/RVP/analyst-ratings"> acquired a total of 21,687 shares </a> an average price of $1.28. To acquire these shares, it cost around $27,768.</li>
<li>What&rsquo;s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
<h3>Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cia#NYSE">CIA</a>) President and CEO Gerald Shields <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 29,182 shares at </a> at an average price of $3.00. To acquire these shares, it cost around $87,546.</li>
<li>What&rsquo;s Happening: The company said total revenues rose to $59.4 million in the third quarter from $56.2 million in the year-ago period.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/02/37210537/top-4-tech-stocks-that-may-crash-this-month"> Top 4 Tech Stocks That May Crash This Month </a>
<h3>Beasley Broadcast Group </h3>
<ul>
<li>The Trade: Beasley Broadcast Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbgi#NASDAQ">BBGI</a>) Chief Operating Officer Brian E Beasley <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 1,200 shares </a> at an average price of $0.85. The insider spent around $1,020 to buy those shares.</li>
<li>What&rsquo;s Happening: Beasley Broadcast posted downbeat fourth-quarter sales.</li>
<li>What Beasley Broadcast Group Does: Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States.</li>
</ul>
<h3>Rezolute </h3>
<ul>
<li>The Trade: Rezolute, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rzlt#NASDAQ">RZLT</a>) CFO Daron Evans <a href="https://www.benzinga.com/quote/RZLT/analyst-ratings"> acquired a total of 50,900 shares </a> at an average price of $1.35. The insider spent around $66,741 to buy those shares.</li>
<li>What&rsquo;s Happening: Rezolute posted a narrower-than-expected quarterly loss.</li>
<li>What Rezolute Does: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies.</li>
</ul>

Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
&nbsp;

BBGI

RZLT

Rezolute And 3 Other Penny Stocks Insiders Are Buying

<a href="https://pro.benzinga.com/?utm_source=insights">According to Benzinga Pro</a> following are the gainers and losers in <a href="https://www.benzinga.com/money/insurance/">Insurance</a> industry for today's Intraday session. 
<h3>Gainers</h3>
<ul>
<li>Maiden Holdings, Ltd. 6.625% Notes due 2046 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHLA#NYSE">MHLA</a>) shares increased by 6.38% to $16.49 during Thursday's regular session. As of 12:40 EST, this security is trading at a volume of 136 shares, making up 0% of its average full-day volume over the last 100 days. </li>
<li>Tian Ruixiang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) shares increased by 5.11% to $0.58. Tian Ruixiang Holdings's stock is trading at a volume of 174.7K shares as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $2.0 million. </li>
<li>Fanhua (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANH#NASDAQ">FANH</a>) shares rose 4.35% to $5.75. As of 12:40 EST, Fanhua's stock is trading at a volume of 8.1K, which is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $340.4 million. </li>
<li>Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) shares increased by 4.28% to $3.65. Trading volume for Cheche Group's stock is 14.6K as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $319.1 million. </li>
<li>Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) shares moved upwards by 4.2% to $29.48. Trupanion's stock is trading at a volume of 172.7K shares as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Kingstone Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KINS#NASDAQ">KINS</a>) stock moved upwards by 2.41% to $3.35. The current volume of 11.1K shares is 0% of Kingstone Companies's average full-day volume over the last 100 days (last updated at 12:40 EST). The company's market cap stands at $33.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) shares fell 8.19% to $352.51 during Thursday's regular session. As of 12:40 EST, Everest Group's stock is trading at a volume of 832.1K, which is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $16.0 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) stock decreased by 4.77% to $1.0. Trading volume for Waterdrop's stock is 167.4K as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $400.7 million. </li>
<li>RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) shares decreased by 3.6% to $226.12. RenaissanceRe Holdings's stock is trading at a volume of 311.6K shares as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.3 billion. </li>
<li>Citizens (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) shares decreased by 3.06% to $2.69. Trading volume for Citizens's stock is 6.6K as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $140.2 million. </li>
<li>Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) shares decreased by 2.59% to $82.24. Arch Capital Group's stock is trading at a volume of 823.7K shares as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $31.5 billion. </li>
<li>CNO Finl Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNO#NYSE">CNO</a>) shares decreased by 2.44% to $26.79. Trading volume for CNO Finl Group's stock is 318.0K as of 12:40 EST. This is 0% of its average full-day volume over the last 100 days. The company's market cap stands at $3.0 billion. As per the press release, Q4 earnings came out 2 days ago. </li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

FANH

KINS

TIRX

Insurance Stocks Moving In Thursday's Intraday Session

Press Releases

Citizens, Inc. Announces Filing of Form S-3 to Replace Expiring Shelf Registration Statement

Citizens, Inc. Vice President of Operations Bryon Matthew Lewis Appointed Chief Operating Officer

Citizens, Inc. Vice President of Information Technology Paula Guerrero Appointed Chief Information Officer

Citizens, Inc. Reports Full Year and Fourth Quarter 2024 Financial Results

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

Comments

Citizens

Noticias

Últimas noticias sobre Citizens (NYSE:CIA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL